×
IMMURON Net Cash Flow 2018-2024 | IMRN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
IMMURON net cash flow from 2018 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
IMMURON Net Cash Flow 2018-2024 | IMRN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
IMMURON net cash flow from 2018 to 2024. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$220.6B
Amgen (AMGN)
$158.8B
Gilead Sciences (GILD)
$136.4B
Vertex Pharmaceuticals (VRTX)
$120.4B
Bristol Myers Squibb (BMY)
$95.4B
GSK (GSK)
$78.4B
CSL (CSLLY)
$76.6B
Regeneron Pharmaceuticals (REGN)
$61.3B
Alnylam Pharmaceuticals (ALNY)
$41.1B
Argenex SE (ARGX)
$34.2B
BioNTech SE (BNTX)
$27.1B
Royalty Pharma (RPRX)
$20.2B
Biogen (BIIB)
$19.7B
Insmed (INSM)
$18.6B
Illumina (ILMN)
$15.7B
Genmab (GNMSF)
$14.2B
Genmab (GMAB)
$13.7B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$13B
Exelixis (EXEL)
$12.2B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.7B
Ascendis Pharma (ASND)
$10.7B
Swedish Orphan Biovitrum (BIOVF)
$10.4B
Exact Sciences (EXAS)
$9.8B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Bio-Techne Corp (TECH)
$8.5B
Blueprint Medicines (BPMC)
$8.4B
Roivant Sciences (ROIV)
$7.7B
Repligen (RGEN)
$7.3B